Susquehanna International Group
CLSD

Susquehanna International Group’s Clearside Biomedical CLSD Stock Holding History

Susquehanna International Group’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,975
Closed -$71.7K – 12561
2025
Q2 		$71.7K Buy
5,975
+3,764
+170% +$46.7K ﹤0.01% 11975
2025
Q1 		$30.4K Sell
2,211
-1,725
-44% -$24.8K ﹤0.01% 12006
2024
Q4 		$56.1K Buy
3,936
+2,581
+190% +$42.4K ﹤0.01% 11631
2024
Q3 		$25.8K Buy
+1,355
New +$23.1K ﹤0.01% 11569
2024
Q1 		– Sell
-6,006
Closed -$129K – 12291
2023
Q4 		$105K Buy
6,006
+2,073
+53% +$29.6K ﹤0.01% 11286
2023
Q3 		$51.3K Buy
3,933
+1,444
+58% +$21.9K ﹤0.01% 11298
2023
Q2 		$41.8K Buy
2,489
+77
+3% +$1.33K ﹤0.01% 11399
2023
Q1 		$37.6K Buy
2,412
+1,105
+85% +$21.5K ﹤0.01% 11824
2022
Q4 		$22K Sell
1,307
-7,761
-86% -$140K ﹤0.01% 11737
2022
Q3 		$154K Sell
9,068
-2,093
-19% -$45.9K ﹤0.01% 11196
2022
Q2 		$246K Buy
11,161
+4,238
+61% +$103K ﹤0.01% 10105
2022
Q1 		$238K Sell
6,923
-11,534
-62% -$345K ﹤0.01% 10819
2021
Q4 		$761K Sell
18,457
-6,664
-27% -$432K ﹤0.01% 8014
2021
Q3 		$2.26M Buy
25,121
+22,604
+898% +$1.99M ﹤0.01% 5566
2021
Q2 		$184K Sell
2,517
-7,155
-74% -$333K ﹤0.01% 11675
2021
Q1 		$358K Buy
9,672
+7,862
+434% +$395K ﹤0.01% 10231
2020
Q4 		$74K Buy
1,810
+242
+15% +$6.28K ﹤0.01% 10623
2020
Q3 		$36K Sell
1,568
-5,191
-77% -$134K ﹤0.01% 10283
2020
Q2 		$191K Sell
6,759
-30,993
-82% -$913K ﹤0.01% 9069
2020
Q1 		$963K Buy
37,752
+17,101
+83% +$632K ﹤0.01% 5495
2019
Q4 		$898K Buy
+20,651
New +$434K ﹤0.01% 5740
2018
Q4 		– Sell
-1,515
Closed -$71.1K – 9024
2018
Q3 		$140K Buy
+1,515
New +$180K ﹤0.01% 8453
2017
Q1 		– Sell
-871
Closed -$117K – 9020
2016
Q4 		$117K Buy
+871
New +$219K ﹤0.01% 8997

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group's CLSD Position: Q3 2025 in Review

Susquehanna International Group sold out of Clearside Biomedical (CLSD) in Q3 2025, closing a stake of 5,975 shares — an estimated $71.7K sold.

Susquehanna International Group first reported a position in CLSD in Q4 2016 and held it in 23 quarters. The position peaked at $2.26M in Q3 2021. 26 funds tracked by Wall St. Rank hold CLSD as of Q3 2025.

  • Susquehanna International Group reported no remaining Clearside Biomedical position as of Q3 2025 after selling out during the quarter.
  • Susquehanna International Group sold 5,975 Clearside Biomedical shares in Q3 2025, an estimated $71.7K.
  • Susquehanna International Group first reported a position in Clearside Biomedical in Q4 2016 and held it in 23 quarters.
  • Susquehanna International Group's Clearside Biomedical position peaked at $2.26M in Q3 2021.
  • 26 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.